Beyond HER2: Targeting the ErbB receptor family in breast cancer.

[1]  Sung-Bae Kim,et al.  Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer , 2022, New England Journal of Medicine.

[2]  H. Iwata,et al.  Results from the phase 1/2 study of patritumab deruxtecan, a HER3-directed antibody-drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC). , 2022, Journal of Clinical Oncology.

[3]  J. Jassem,et al.  166MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Initial results from BEGONIA, a phase Ib/II study , 2022, Annals of Oncology.

[4]  B. González-Farré,et al.  LBA3 Patritumab deruxtecan (HER3-DXd) in early-stage HR+/HER2- breast cancer: Final results of the SOLTI TOT-HER3 window of opportunity trial , 2022, Annals of Oncology.

[5]  Min Hwan Kim,et al.  Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. , 2022, The New England journal of medicine.

[6]  Toshio Shimizu,et al.  TROPION-PanTumor01: Dose analysis of the TROP2-directed antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd, DS-1062) for the treatment (Tx) of advanced or metastatic non-small cell lung cancer (NSCLC). , 2021 .

[7]  Ying Cheng,et al.  Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial. , 2021, The Lancet. Oncology.

[8]  S. Chandarlapaty,et al.  Unlocking the potential of antibody–drug conjugates for cancer therapy , 2021, Nature Reviews Clinical Oncology.

[9]  A. Letai,et al.  Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer , 2020, Breast cancer research : BCR.

[10]  E. Yang,et al.  Anti‐EGFR antibody‐drug conjugate for triple‐negative breast cancer therapy , 2020, Engineering in life sciences.

[11]  R. Xu,et al.  First-in-human dose-escalation study of anti-EGFR ADC MRG003 in patients with relapsed/refractory solid tumors. , 2020 .

[12]  J. Bendell,et al.  Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE). , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  Sung-Bae Kim,et al.  Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. , 2019, The New England journal of medicine.

[14]  Ying Cheng,et al.  Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. , 2019, The New England journal of medicine.

[15]  I. Meinhold-Heerlein,et al.  Molecular Targeting Therapy against EGFR Family in Breast Cancer: Progress and Future Potentials , 2019, Cancers.

[16]  F. Bidard,et al.  ERBB3 mutations in cancer: biological aspects, prevalence and therapeutics , 2019, Oncogene.

[17]  D. Cunningham,et al.  Targeting EGFR pathway in metastatic colorectal cancer- tumour heterogeniety and convergent evolution. , 2019, Critical reviews in oncology/hematology.

[18]  G. Brockhoff.  Target HER four in breast cancer? , 2019, Oncotarget.

[19]  Bolin Liu,et al.  Development of Effective Therapeutics Targeting HER3 for Cancer Treatment , 2019, Biological Procedures Online.

[20]  P. Fasching,et al.  Trastuzumab Emtansine for Residual Invasive HER2‐Positive Breast Cancer , 2019, The New England journal of medicine.

[21]  B. Taylor,et al.  The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. , 2018, Cancer cell.

[22]  J. Zugazagoitia,et al.  Targeting EGFR in Lung Cancer: Current Standards and Developments , 2018, Drugs.

[23]  A. Schneeweiss,et al.  Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer , 2018, Investigational New Drugs.

[24]  B. Taylor,et al.  HER kinase inhibition in patients with HER2- and HER3-mutant cancers , 2018, Nature.

[25]  J. Grandis,et al.  EGFR-targeted therapies in the post-genomic era , 2017, Cancer and Metastasis Reviews.

[26]  A. Scott,et al.  Antibody–drug conjugates in glioblastoma therapy: the right drugs to the right cells , 2017, Nature Reviews Clinical Oncology.

[27]  S. Loibl,et al.  HER2-positive breast cancer , 2017, The Lancet.

[28]  J. Hainsworth,et al.  Panitumumab, Gemcitabine, and Carboplatin as Treatment for Women With Metastatic Triple-Negative Breast Cancer: A Sarah Cannon Research Institute Phase II Trial. , 2016, Clinical breast cancer.

[29]  Hirohito Yamaguchi,et al.  A perspective on anti-EGFR therapies targeting triple-negative breast cancer. , 2016, American journal of cancer research.

[30]  F. Penault-Llorca,et al.  Multicentric neoadjuvant pilot Phase II study of cetuximab combined with docetaxel in operable triple negative breast cancer , 2016, International journal of cancer.

[31]  Chiun-Sheng Huang,et al.  Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial. , 2016, The Lancet. Oncology.

[32]  E. Perez,et al.  N0436 (Alliance): A Phase II Trial of Irinotecan With Cetuximab in Patients With Metastatic Breast Cancer Previously Exposed to Anthracycline and/or Taxane-Containing Therapy. , 2016, Clinical breast cancer.

[33]  K. Tsuchihashi,et al.  Development of an ErbB4 monoclonal antibody that blocks neuregulin-1-induced ErbB4 activation in cancer cells. , 2016, Biochemical and biophysical research communications.

[34]  Eunyoung Kang,et al.  High EGFR gene copy number predicts poor outcome in triple-negative breast cancer , 2014, Modern Pathology.

[35]  F. Penault-Llorca,et al.  Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  Aiko Sueta,et al.  The localization of HER4 intracellular domain and expression of its alternately-spliced isoforms have prognostic significance in ER+ HER2- breast cancer , 2014, Oncotarget.

[37]  A. Harris,et al.  Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer. , 2014, Oncotarget.

[38]  Borivoj Vojnovic,et al.  Antagonism of EGFR and HER3 Enhances the Response to Inhibitors of the PI3K-Akt Pathway in Triple-Negative Breast Cancer , 2014, Science Signaling.

[39]  R. Greil,et al.  Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  J. Ahn,et al.  Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) who received taxane plus trastuzumab treatment , 2013, British Journal of Cancer.

[41]  Somasekar Seshagiri,et al.  Oncogenic ERBB3 mutations in human cancers. , 2013, Cancer cell.

[42]  C. Sotiriou,et al.  Pertuzumab: new hope for patients with HER2-positive breast cancer. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[43]  J. Baselga,et al.  Trastuzumab emtansine for HER2-positive advanced breast cancer. , 2012, The New England journal of medicine.

[44]  Zhuo Georgia Chen,et al.  Advances in Targeting HER3 as an Anticancer Therapy , 2012, Chemotherapy research and practice.

[45]  Hiroko Masuda,et al.  Role of epidermal growth factor receptor in breast cancer , 2012, Breast Cancer Research and Treatment.

[46]  Anastasia Ivanova,et al.  TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  Gur Pines,et al.  The ERBB network: at last, cancer therapy meets systems biology , 2012, Nature Reviews Cancer.

[48]  M. Beckmann,et al.  A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer , 2012, Breast Cancer Research and Treatment.

[49]  J. Murray,et al.  A phase I/II study of MM-111, a novel bispecific antibody that targets the ErB2/ErB3 heterodimer, in combination with trastuzumab in advanced refractory HER2-positive breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  S. Chandarlapaty,et al.  HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies , 2011, Expert review of anticancer therapy.

[51]  S. Chandarlapaty,et al.  PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer , 2011, Oncogene.

[52]  Sarat Chandarlapaty,et al.  AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. , 2011, Cancer cell.

[53]  R. Schiff,et al.  Gefitinib or Placebo in Combination with Tamoxifen in Patients with Hormone Receptor–Positive Metastatic Breast Cancer: A Randomized Phase II Study , 2011, Clinical Cancer Research.

[54]  Jorge S Reis-Filho,et al.  Triple-negative breast cancer. , 2010, The New England journal of medicine.

[55]  S. Wiseman,et al.  HER-3 Overexpression Is Prognostic of Reduced Breast Cancer Survival: A Study of 4046 Patients , 2010, Annals of surgery.

[56]  G. Iconomou,et al.  The upgraded role of HER3 and HER4 receptors in breast cancer. , 2010, Critical reviews in oncology/hematology.

[57]  R Snyder,et al.  Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[58]  F. Hofstaedter,et al.  Presence of HER4 associates with increased sensitivity to Herceptin™ in patients with metastatic breast cancer , 2009, Breast Cancer Research.

[59]  D. Laber,et al.  Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers , 2009, Journal of oncology.

[60]  E. Winer,et al.  Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer , 2009, Breast Cancer Research and Treatment.

[61]  N. Hynes,et al.  ErbB receptors and signaling pathways in cancer. , 2009, Current opinion in cell biology.

[62]  M. Sliwkowski,et al.  Suppression of breast cancer cell growth by a monoclonal antibody targeting cleavable ErbB4 isoforms , 2009, Oncogene.

[63]  C. Boni,et al.  Phase II, randomized trial of preoperative epirubicin-paclitaxel +/− gefitinib with biomarker evaluation in operable breast cancer , 2008, Breast Cancer Research and Treatment.

[64]  Arndt Hartmann,et al.  Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients , 2008, Breast Cancer Research.

[65]  A. Tutt,et al.  Triple negative tumours: a critical review , 2007, Histopathology.

[66]  M. Dowsett,et al.  A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  C. Hudis,et al.  A phase I study of cetuximab/paclitaxel in patients with advanced-stage breast cancer. , 2006, Clinical breast cancer.

[68]  J. Baselga,et al.  Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  Motonori Yamaguchi,et al.  Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibition. , 2003, Anticancer research.

[70]  E. Rowinsky,et al.  The ErbB receptor family: a therapeutic target for cancer. , 2002, Trends in molecular medicine.

[71]  Yosef Yarden,et al.  Biology of HER2 and Its Importance in Breast Cancer , 2001, Oncology.

[72]  Y. Yarden.  The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. , 2001, European journal of cancer.

[73]  L. Caskey,et al.  HER4 Mediates Ligand-Dependent Antiproliferative and Differentiation Responses in Human Breast Cancer Cells , 2001, Molecular and Cellular Biology.

[74]  J. Ross,et al.  The HER‐2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy , 1998, The oncologist.

[75]  D. Stern,et al.  Specificity within the EGF family/ErbB receptor family signaling network , 1998, BioEssays : news and reviews in molecular, cellular and developmental biology.

[76]  M. Kraus,et al.  Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. , 1995, Oncogene.

[77]  W. Gullick,et al.  A monoclonal antibody to the human c-erbB3 protein stimulates the anchorage-independent growth of breast cancer cell lines. , 1994, British Journal of Cancer.

[78]  G. Plowman,et al.  Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[79]  C. Cordon-Cardo,et al.  Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. , 1990, Oncogene.

[80]  G. Carpenter,et al.  Characterization of the binding of 125-I-labeled epidermal growth factor to human fibroblasts. , 1975, The Journal of biological chemistry.

[81]  E. Felip,et al.  Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[82]  Zhixiang Wang.  ErbB Receptors and Cancer. , 2017, Methods in molecular biology.

[83]  M. Piccart,et al.  A European Organisation for Research and Treatment of Cancer randomized, double-blind, placebo-controlled, multicentre phase II trial of anastrozole in combination with gefitinib or placebo in hormone receptor-positive advanced breast cancer (NCT00066378). , 2016, European journal of cancer.

[84]  P. Fasching,et al.  A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer , 2004, Breast Cancer Research and Treatment.